Back to News
Market Impact: 0.2
Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Tenax Therapeutics reported $113.7 million in cash and cash equivalents as of September 30, 2026, and a third-quarter 2026 net loss of $16.7 million. The article text is truncated before the prior-period comparison is complete, so no year-over-year change can be assessed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
-0.05
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook